Groupe d'Etude en Oncologie du Quebec

Titre	Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer
Protocole ID	ANCHOR-Prostate
ClinicalTrials.gov ID	NCT05457699
Type(s) de cancer	Prostate
Phase	Phase II
Stade	Métastatique
Type étude	Clinique
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dre Cynthia Ménard
Coordonnateur(trice)	Mom Phat 514-890-8000 poste 11171
Statut	Actif en recrutement
Date d'activation	09-01-2023
Critètes d'éligibilité	Enrolled in PERa (CHUM CER 17.032) and randomly selected for AnChoR-Prostate. Diagnosis of metastatic prostate cancer having achieved maximum PSA response to SOC systemic therapy defined as two consecutive stable PSA within 6 months of regimen start. Stable PSA is defined as non- progressing (<25% rise from nadir, per PCWG3 guidelines). ECOG 0-2 PSA > 0.2 ng/mL 1-5 sites of PSMA-PET avid disease amenable to SABR.
Critètes d'exclusion	none

Groupe d'étude en oncologie du Québec